For cancer patients, every day of treatment is critical. But the best care possible is not always reaching patients quickly. Despite Health Canada approving a drug treating an aggressive blood cancer, a complex web of organizations, insurance plans and negotiations over drug pricing means it’s still not available in Canada.
Globe reporters Kelly Grant, who covers health, and Chris Hannay, who covers the business of health care, tell us what is holding up life-changing drugs and why Canadian patients are the ones left with the consequences.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
